Premium
Rosiglitazone selectively inhibits K ATP channels by acting on the K IR 6 subunit
Author(s) -
Yu Lei,
Jin Xin,
Cui Ningren,
Wu Yang,
Shi Zhenda,
Zhu Daling,
Jiang Chun
Publication year - 2012
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2012.01934.x
Subject(s) - rosiglitazone , chemistry , pinacidil , sulfonylurea receptor , potassium channel , patch clamp , ic50 , gene isoform , glibenclamide , protein subunit , biophysics , stereochemistry , receptor , endocrinology , biochemistry , in vitro , biology , diabetes mellitus , gene
Rosiglitazone is an anti-diabetic drug acting as an insulin sensitizer. We recently found that rosiglitazone also inhibits the vascular isoform of ATP-sensitive K(+) channels and compromises vasodilatory effects of β-adrenoceptor activation and pinacidil. As its potency for the channel inhibition is in the micromolar range, rosiglitazone may be used as an effective K(ATP) channel inhibitor for research and therapeutic purposes. Therefore, we performed experiments to determine whether other isoforms of K(ATP) channels are also sensitive to rosiglitazone and what their sensitivities are.